Armata Pharma Q1 operating loss $10.2M; secures $35M loan at 14% from Innoviva

Armata Pharmaceuticals, Inc.

2024-Q1 EPS reported -$0.69

Grant revenue $1.0M (up from $0.8M YoY); R&D expense $8.0M (down from $9.6M); G&A $3.2M (up from $2.5M).
Cash $37.9M as of March 31, 2024 vs $13.5M at Dec 31, 2023, aided by $35M credit agreement with Innoviva arm.
Loan bears 14% annual interest, matures June 4, 2025; principal and interest payable at maturity.
Phase 2a diSArm (AP-SA02) and Phase 2 Tail wind (AP-PA02) advancing; enrollment on track.
cGMP manufacturing build-out expected mid-2024; R&D labs and admin space already operational.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Armata Pharmaceuticals, Inc. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 7, 2024, Armata Pharmaceuticals, Inc. (the “Company”) announced its financial results for the three months ended March 31, 2024, in the press release furnished hereto as Exhibit 99.1.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Armata Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-007060

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.